AstraZeneca Pharma India Limited had earlier announced the receipt of Import and Market Permission in Form 45 (Marketing Authorization) from the Drugs Controller General of India for FDC of Dapagliflozin 10mg + Saxagliptin 5mg film coated tablets (QTERN®).
The company has now commenced the launch of QTERN® in India.
FDC of Dapagliflozin 10mg + Saxagliptin 5mg is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus (T2DM).
Shares of ASTRAZENECA PHARMA INDIA LTD. was last trading in BSE at Rs.2802 as compared to the previous close of Rs. 2848.4. The total number of shares traded during the day was 1372 in over 320 trades.
The stock hit an intraday high of Rs. 2882.1 and intraday low of 2794. The net turnover during the day was Rs. 3886451.-Equity Bulls